Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases

Biologic treatment options such as tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis. Recent data suggest, however, that full and long-lasting responses to TNF inhibitors are limited because of the activation of the pro-...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:MAbs
Päätekijät: Silacci, Michela, Lembke, Wibke, Woods, Richard, Attinger-Toller, Isabella, Baenziger-Tobler, Nadja, Batey, Sarah, Santimaria, Roger, von der Bey, Ulrike, Koenig-Friedrich, Susann, Zha, Wenjuan, Schlereth, Bernd, Locher, Mathias, Bertschinger, Julian, Grabulovski, Dragan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2015
Aiheet:
Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966518/
https://ncbi.nlm.nih.gov/pubmed/26390837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1093266
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia